TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
BIO-TECHNE Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 24, 2026
$72.49−0.08 (-0.11%)
Close on Oct 19, 2026
- Market cap
- $11.40B
- P/E (TTM)
- 62.5
- Dividend yield
- 0.44%
BIO-TECHNE Corp revenue by segment
By business segment
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $231.19M | $226.15M | $215.08M | $202.19M | $226.47M | $227.69M | $211.55M | $204.54M | $213.99M | $214.59M | $197.67M | $204.66M | 72.0% | +2.1% |
| Diagnostics and Spatial Biology | $90.14M | $85.59M | $81.18M | $79.46M | $89.71M | $89.23M | $84.14M | $83.19M | $90.68M | $87.51M | $75.41M | $72.80M | 28.1% | +0.5% |
| Diagnostics and Genomics | – | – | – | – | – | – | – | – | $90.68M | $87.51M | $75.41M | $72.80M | – | – |
| Other Revenues from Business Held for Sale | – | – | – | – | – | $0 | $1.85M | $2.30M | $2.06M | $2.09M | – | – | – | – |
| Operating income | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $97.07M | $100.00M | $84.62M | $77.71M | $98.79M | $103.91M | $87.11M | $80.54M | $92.00M | $94.83M | $79.59M | $88.36M | -1.7% |
| Diagnostics and Spatial Biology | $10.07M | $10.32M | $8.43M | $8.88M | $5.38M | $8.42M | $3.24M | $4.28M | $11.36M | $8.10M | $4.56M | $527.00K | +87.0% |
| Diagnostics and Genomics | – | – | – | – | – | – | – | – | $11.36M | $8.10M | $4.56M | $527.00K | – |
By product or service
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and Services | $315.33M | $306.45M | $287.36M | $280.91M | $311.46M | $311.14M | $288.93M | $284.41M | $301.05M | $298.73M | $265.08M | $270.86M | 98.2% | +1.2% |
| Consumables | $260.73M | $257.34M | $235.44M | $231.60M | $252.94M | $257.79M | $230.72M | $230.85M | $245.78M | $246.73M | $211.13M | $224.55M | 81.2% | +3.1% |
| Instruments | $31.54M | $27.66M | $29.61M | $21.83M | $28.90M | $26.11M | $30.87M | $26.21M | $27.09M | $26.49M | $29.83M | $24.86M | 9.8% | +9.1% |
| Services | $23.06M | $21.45M | $22.32M | $27.48M | $29.62M | $27.25M | $27.35M | $27.36M | $28.18M | $25.50M | $24.13M | $21.45M | 7.2% | -22.1% |
| Royalty revenues | $5.87M | $4.97M | $8.51M | $5.65M | $5.51M | $5.04M | $8.10M | $5.05M | $5.05M | $4.70M | $7.52M | $6.07M | 1.8% | +6.5% |
By region
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $166.10M | $167.48M | $146.56M | $155.24M | $176.39M | $181.92M | $159.91M | $165.02M | $177.53M | $173.32M | $147.79M | $159.11M | 51.7% | -5.8% |
| EMEA, excluding United Kingdom | $80.29M | $73.45M | $75.35M | $65.13M | $70.35M | $66.50M | $70.39M | $59.06M | $63.57M | $60.53M | $62.54M | $54.80M | 25.0% | +14.1% |
| China | $26.91M | $26.01M | $26.35M | $24.79M | $26.91M | $24.48M | $24.75M | $24.32M | $23.93M | $25.60M | $24.46M | $25.49M | 8.4% | +0.0% |
| APAC, excluding Greater China | $22.11M | $21.82M | $22.74M | $19.15M | $18.89M | $21.25M | $19.01M | $18.12M | $19.26M | $18.25M | $19.04M | $17.35M | 6.9% | +17.0% |
| United Kingdom | $14.46M | $14.89M | $13.73M | $13.21M | $14.79M | $12.85M | $13.24M | $13.94M | $11.76M | $15.12M | $10.68M | $12.45M | 4.5% | -2.2% |
| Rest of World | $11.32M | $7.77M | $11.15M | $9.05M | $9.65M | $9.18M | $9.73M | $8.99M | $10.05M | $10.61M | $8.09M | $7.75M | 3.5% | +17.4% |
From the segment and revenue-disaggregation notes of Bio-Techne's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.